Lee Golden, M.D., Chairman of the Board of Directors
Dr. Golden is currently Chief Medical Officer at Gemphire (NASDAQ:GEMP), a clinical-stage biopharmaceutical company that is developing and commercializing therapies to help patients with cardiometabolic disorders, including dyslipidemia and NASH. Prior to that, he served as Senior VP, Therapeutic Business Unit Head for Cardiovascular, Pulmonary and Central Nervous System at Mesoblast (NASDAQ:MESO). Dr. Golden is an expert in the oversight of large cardiovascular trials and development of new cardiovascular/blood therapeutics. He has served as Executive Director of Neuroscience and Ophthalmology at Novartis Pharmaceuticals, Cardiovascular Executive Director at Eisai Medical Research, and Cardiovascular Team Leader/Medical Director at Pfizer Pharmaceuticals. Dr. Golden has managed global cross-functional teams responsible for creating and implementing strategic development and commercial plans. Dr. Golden is a graduate of New York University School of Medicine and is formally trained as an Interventional Cardiologist.
Sheldon Goldstein, M.D., Founder & CEO
Dr. Goldstein is the inventor of the MCTS™ device and the visionary behind the Company’s blood transfusion-related Intellectual Property. Dr. Goldstein is an Internist & Cardiac Anesthesiologist practicing at Montefiore Medical Center, having received his medical degree at Hahnemann Medical College in Philadelphia (renamed Drexel/Hahnemann). Dr. Goldstein is an expert in the management of bleeding patients and has been invited to speak on coagulation and transfusion topics on multiple occasions.
Allen Goldman, BBA/MBA, CPA, Chief Financial Officer
Mr. Goldman has 35 plus years of business and finance experience. He is skilled in financial controls, procedures, and reporting. He has served as CFO/COO of companies ranging in size from $10M to $150M in sales. He also served as an auditor of publicly traded companies for six years.
Jonathan Kusko, JD, LLM, Senior Business Advisor
Retired from practice of law. Formerly a partner at Stroock and Stroock and Lavan LLC where he specialized in federal income tax law with an emphasis on taxation of investment funds and pass-through entities.
Michael Kagan, Director of Product Development
Mr. Kagan leads the development process for the Company’s devices, from prototyping and testing to manufacturing transfer and commercialization. Mr. Kagan brings 28 years of successful experience in the diagnostics industry, having worked at Immunicon, Siemens HealthCare, and Ciba Corning, where he led engineering and manufacturing initiatives that resulted in FDA clearances for six in-vitro medical devices, and the test kits that operate on these platforms.